查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080403

銀屑病治療市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、銀屑病類型、患者人口統計特徵、分銷管道和治療環境分類）

Psoriasis Drugs Market by Drug Class, Route Of Administration, Psoriasis Type, Patient Type, Distribution Channel, Treatment Setting - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乾癬治療市場將成長至 345 億美元，複合年成長率為 10.85%。

主要市場統計數據
基準年 2025 167.7億美元
預計年份：2026年 185.4億美元
預測年份 2032 345億美元
複合年成長率 (%) 10.85%

乾癬的治療正從廣泛的免疫抑制療法轉向精準皮膚病學，治療決策越來越受到疾病嚴重程度、合併乾癬性關節炎、生物製藥使用史、給藥途徑、保險覆蓋範圍和患者意願的影響。世界衛生組織（WHO）已將銀屑病認定為一種系統性、慢性、免疫介導的非傳染性疾病，同行評審的流行病學研究一​​致報告其全球患病率約為2%至3%，但患病率會因地區、種族、年齡和診斷可及性而存在顯著差異。

乾癬的治療方案包括外用皮質類固醇和維生素D類似物、照光治療聯合護理、口服全身治療（如胺基甲基葉酸、Cyclosporine、Apremilast和地克拉伐替尼）以及靶向TNF-α、IL-17、IL-12/23和IL-23通路的生物目標製劑。需求成長的促進因素包括診斷率的提高、生物製藥適應症的擴大、生物相似藥的引入、長期安全性數據的積累，以及患者對皮膚症狀持續改善、治療負擔減輕和給藥方便的期望。

銀屑病治療前景的變革性變化

白細胞介素標靶生物製藥正在重塑市場競爭格局，這些藥物提高了臨床療效預期，從控制症狀到改善嚴重皮膚症狀，包括在大型臨床試驗中報告的PASI 90和PASI 100等療效。 IL-23和IL-17抑制劑正在強化中重度黃斑病變的標準治療方案，而口服療法的創新，包括TYK2抑制劑，則為希望避免注射或尚未準備好接受生物製藥治療的患者提供了更多選擇。

人工智慧對乾癬治療的累積影響

人工智慧 (AI) 正在成為銀屑病治療研發、商業化和推廣中的一股重要力量。在研發領域，AI 驅動的影像分析能夠利用臨床照片更客觀地評估疾病嚴重程度。此外，研究人員也正在探索利用機器學習模型，根據治療反應、合併症風險、復發可能性和用藥依從性模式對患者進行分層。當這些工具與皮膚科醫生的評估相結合併檢驗時，它們有望降低 PASI 評分的變異性，並提高臨床試驗中受試者選擇的準確性。

對主要銀屑病治療市場的關鍵區域洞察。

北美仍然是銀屑病治療的主要地區，這得益於其生物製藥的高使用率、便捷的專科醫生資源、先進的醫保管理以及美國和加拿大FDA批准的標靶治療的快速普及。在歐洲，廣泛的皮膚病學專業知識和嚴格的醫療技術評估相結合，使得報銷標準、療效比較、治療指南以及生物相似藥的價值成為歐盟和英國獲得治療的關鍵因素。

針對特定群體的銀屑病治療獲取和成長的關鍵見解

在東協地區，皮膚科網路的擴張、私立醫院的增加、部分市場的醫療旅遊，以及新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國保險報銷制度的差異，都在影響銀屑病治療的需求。在海灣合作理事會（GCC）國家，大量的醫療保健投資、集中採購系統、國家醫療保險制度的改革以及專家的引進，都極大地促進了合格的中重度銀屑病患者獲得生物製藥的機會。

關於銀屑病治療藥物商業化的關鍵國家概況

美國是銀屑病治療領域最具創新性的市場，這得益於FDA的批准、專科藥房管道、生物製藥在皮膚科應用的悠久歷史以及標靶治療的廣泛應用，儘管支付方的監管對治療順序有著顯著影響。在加拿大，循證報銷和省級准入決策備受重視；而在墨西哥和巴西，由於公共部門預算限制、醫療資源分配不均以及經濟負擔壓力，對先進皮膚病治療的需求日益成長。

為銀屑病治療行業的領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，而非僅依賴進入同一類別。證據資料應提及皮膚症狀的顯著改善、療效的持續性、起效迅速、長期安全性、與乾癬性關節炎的相關性、生活品質的提高以及真實臨床實踐中的治療依從率。製藥公司還需要製定更完善的市場進入計劃，以應對來自生物類似藥的競爭、逐步修改、預核准以及支付方提出的比較性療效要求。

銀屑病治療藥物分析的調查方法

本執行摘要基於一項二手檢驗，該框架使用了公開且可驗證的來源，包括監管資訊、同行評審的皮膚病學文獻、臨床試驗論文、治療指南、流行病學參考文獻、藥物安全監測更新以及衛生技術評估趨勢。參考資訊來源包括世界衛生組織 (WHO)、美國食品藥物管理局(FDA)、歐洲藥品管理局 (EMA)、各國皮膚病學會以及已發表的關於生物製藥、生物類似藥、口服全身療法和標靶免疫調節劑治療乾癬的臨床資訊來源。

結論：銀屑病治療市場的未來發展方向

乾癬治療市場已進入競爭更加激烈、以實證醫學主導的階段，持續緩解症狀、便利性、安全性、可負擔性和可近性都是決定性因素。標靶生物製藥和口服免疫調節劑改變了人們對中重度斑乳頭狀乾癬的預期。同時，生物相似藥、醫療技術評估和保險公司政策正在重塑商業策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 銀屑病治療市場：依藥物類別分類

  • 生物製劑
    • IL-17抑制劑
    • IL-23抑制劑
    • TNF抑制劑
  • 低分子化合物
    • JAK抑制劑
    • PDE4抑制劑

第8章 銀屑病治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 暫停
    • 藥片
  • 外用
    • 奶油
    • 氣泡劑
    • 凝膠
    • 軟膏

第9章：銀屑病治療市場：依銀屑病類型分類

  • 紅皮病型乾癬
  • 水滴狀乾癬
  • 反向銀屑病
  • 指甲銀屑病
  • 斑塊型乾癬
  • 膿皰型乾癬
  • 頭部銀屑病

第10章：銀屑病治療市場：依患者類型分類

  • 成人
  • 老年人
  • 兒童

第11章 銀屑病治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第12章 銀屑病治療市場：依治療領域分類

  • 居家治療
  • 在醫院接受治療
  • 專業皮膚科診所

第13章 銀屑病治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 銀屑病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 銀屑病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Dermavant Sciences Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Viatris Inc.
Product Code: MRR-434CCDA051B5

The Psoriasis Drugs Market is projected to grow by USD 34.50 billion at a CAGR of 10.85% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.77 billion
Estimated Year [2026] USD 18.54 billion
Forecast Year [2032] USD 34.50 billion
CAGR (%) 10.85%

Psoriasis drugs are moving from broad immunosuppression toward precision dermatology, with treatment decisions increasingly shaped by disease severity, comorbid psoriatic arthritis, prior biologic exposure, route of administration, payer access, and patient preference. Psoriasis is recognized by the World Health Organization as a chronic, immune-mediated, noncommunicable disease with systemic impact, and peer-reviewed epidemiology consistently places global prevalence at roughly 2% to 3%, with meaningful variation by geography, ancestry, age, and diagnostic access.

The psoriasis therapeutics landscape spans topical corticosteroids and vitamin D analogs, phototherapy-adjacent care, oral systemic therapies such as methotrexate, cyclosporine, apremilast, deucravacitinib, and targeted biologics directed at TNF-alpha, IL-17, IL-12/23, and IL-23 pathways. Demand is being driven by higher diagnosis rates, expanding biologic eligibility, biosimilar adoption, longer-term safety evidence, and patient expectations for durable skin clearance, lower treatment burden, and convenient dosing.

Transformative Shifts in the Psoriasis Treatment Landscape

The competitive landscape is being reshaped by interleukin-focused biologics that have raised clinical expectations from symptom control to high levels of skin clearance, including PASI 90 and PASI 100 outcomes reported in pivotal trials. IL-23 and IL-17 inhibitors have strengthened the standard of care for moderate-to-severe plaque psoriasis, while oral innovation, including TYK2 inhibition, is widening options for patients who prefer noninjectable therapies or are not ready for biologic treatment.

At the same time, biosimilars are altering pricing dynamics in TNF-alpha therapy and encouraging payers to revisit formulary design, step therapy, and prior authorization criteria. Dermatology practices are adapting to more complex sequencing decisions as clinicians balance efficacy, infection risk, inflammatory bowel disease considerations, psoriatic arthritis activity, cardiometabolic comorbidities, pregnancy planning, and long-term adherence.

Cumulative Impact of Artificial Intelligence on Psoriasis Drugs

Artificial intelligence is becoming a practical force in psoriasis drug development, commercialization, and care delivery. In research, AI-enabled image analysis can support more objective severity assessment using clinical photography, while machine learning models are being explored to stratify patients by treatment response, comorbidity risk, flare probability, and adherence patterns. These tools may reduce variability in PASI scoring and improve trial enrichment when validated against dermatologist-led assessments.

For manufacturers and healthcare systems, AI can improve pharmacovigilance signal detection, medical information workflows, real-world evidence generation, claims analytics, and patient support personalization. However, adoption must remain clinically governed because psoriasis datasets can underrepresent darker skin tones and underserved populations, creating bias risks in diagnostic tools, severity algorithms, and digital triage platforms.

Key Regional Insights Across Major Psoriasis Drug Markets

North America remains a leading region for psoriasis drugs because of high biologic utilization, strong specialist access, advanced payer management, and rapid uptake of FDA-approved targeted therapies in the United States and Canada. Europe combines broad dermatology expertise with stringent health technology assessment, making reimbursement evidence, comparative effectiveness, treatment guidelines, and biosimilar value central to access across the European Union and the United Kingdom.

Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia improve specialty care capacity and increase access to biologics and oral targeted therapies, although affordability, reimbursement depth, and urban-rural dermatology access vary widely. Latin America, led by Brazil and Mexico, shows rising demand for advanced therapies but remains sensitive to public procurement, reimbursement delays, and out-of-pocket costs. The Middle East, particularly GCC markets, is investing in specialty care infrastructure and centralized access pathways, while Africa continues to face diagnosis gaps, uneven dermatology access, and limited availability of high-cost biologics outside major urban centers.

Key Group Insights for Psoriasis Drug Access and Growth

Within ASEAN, psoriasis drug demand is influenced by growing dermatology networks, private hospital expansion, medical tourism in selected markets, and variable reimbursement across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC benefits from high healthcare investment, centralized procurement, national insurance reforms, and increasing specialist availability, supporting access to biologics for eligible moderate-to-severe patients.

The European Union is shaped by coordinated regulatory standards, country-level reimbursement negotiations, clinical guideline adoption, and strong biosimilar policies that influence pricing and access. BRICS markets represent a major long-term opportunity because of large patient pools, expanding local pharmaceutical capabilities, and rising specialist care capacity, though affordability and public funding remain decisive. G7 countries continue to set clinical, regulatory, and pharmacovigilance benchmarks, while NATO member markets overlap substantially with advanced North American and European systems where supply resilience, quality standards, reimbursement scrutiny, and medicine security are prominent.

Key Country Insights in Psoriasis Drug Commercialization

The United States is the most innovation-intensive psoriasis drug market, supported by FDA approvals, specialty pharmacy channels, dermatology biologic experience, and broad use of targeted therapies, though payer controls strongly influence treatment sequencing. Canada emphasizes evidence-based reimbursement and provincial access decisions, while Mexico and Brazil show increasing demand for advanced dermatology care amid public-sector budget constraints, uneven access, and affordability pressure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are characterized by strong guideline adoption, health technology assessment, structured reimbursement, and growing biosimilar use, while Russia faces more localized access, registration, and procurement dynamics. China is expanding access through regulatory modernization, accelerated review pathways, and national reimbursement mechanisms; India remains highly price-sensitive with growing specialist adoption in urban centers; Japan and South Korea maintain sophisticated dermatology markets with strong clinical governance; and Australia benefits from structured reimbursement through established public funding mechanisms that support eligible patients with moderate-to-severe disease.

Actionable Recommendations for Psoriasis Drug Industry Leaders

Industry leaders should prioritize differentiated clinical value rather than relying solely on class participation. Evidence packages should address high skin clearance, durability, speed of onset, long-term safety, psoriatic arthritis relevance, quality-of-life improvement, and real-world persistence. Manufacturers also need stronger market access planning that anticipates biosimilar competition, step edits, prior authorization, and payer demand for comparative outcomes.

Organizations should invest in inclusive clinical trials, skin-of-color evidence, patient support programs, digital adherence tools, and education that reduces treatment discontinuation and underdiagnosis. Regional strategies must reflect reimbursement realities: value dossiers for Europe, payer navigation in North America, affordability models in emerging markets, tender readiness in public procurement systems, and evidence generation that supports both clinical confidence and equitable access.

Research Methodology for Psoriasis Drugs Analysis

This executive summary is based on a secondary-research framework using publicly available and verifiable sources, including regulatory agency information, peer-reviewed dermatology literature, clinical trial publications, treatment guidelines, epidemiology references, pharmacovigilance updates, and health technology assessment patterns. Sources considered include organizations such as the World Health Organization, U.S. Food and Drug Administration, European Medicines Agency, national dermatology associations, and published clinical evidence on psoriasis biologics, biosimilars, oral systemic therapies, and targeted immune modulators.

The analysis integrates therapeutic class dynamics, regional access conditions, policy factors, technology trends, and real-world care considerations. It avoids unsupported market-size claims and emphasizes evidence-backed drivers such as psoriasis prevalence, biologic innovation, biosimilar uptake, reimbursement controls, comorbidity management, and AI-enabled clinical and commercial applications.

Conclusion: Future Direction of the Psoriasis Drugs Market

The psoriasis drugs market is entering a more competitive, evidence-driven phase where durable clearance, convenience, safety, affordability, and access are all decisive. Targeted biologics and oral immune modulators have transformed expectations for moderate-to-severe plaque psoriasis, while biosimilars, health technology assessment, and payer policies are reshaping commercial strategy.

Future success will depend on proving differentiated value across diverse patient populations and healthcare systems. Organizations that combine strong clinical evidence, equitable access planning, AI-enabled insights, inclusive real-world data, and disciplined regional execution will be best positioned to lead in the evolving psoriasis therapeutics landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Psoriasis Drugs Market, by Drug Class

  • 7.1. Biologics
    • 7.1.1. IL 17 Inhibitors
    • 7.1.2. IL 23 Inhibitors
    • 7.1.3. TNF Inhibitors
  • 7.2. Small Molecules
    • 7.2.1. JAK Inhibitors
    • 7.2.2. PDE4 Inhibitors

8. Psoriasis Drugs Market, by Route Of Administration

  • 8.1. Injectable
    • 8.1.1. Intravenous
    • 8.1.2. Subcutaneous
  • 8.2. Oral
    • 8.2.1. Capsules
    • 8.2.2. Suspensions
    • 8.2.3. Tablets
  • 8.3. Topical
    • 8.3.1. Creams
    • 8.3.2. Foams
    • 8.3.3. Gels
    • 8.3.4. Ointments

9. Psoriasis Drugs Market, by Psoriasis Type

  • 9.1. Erythrodermic Psoriasis
  • 9.2. Guttate Psoriasis
  • 9.3. Inverse Psoriasis
  • 9.4. Nail Psoriasis
  • 9.5. Plaque Psoriasis
  • 9.6. Pustular Psoriasis
  • 9.7. Scalp Psoriasis

10. Psoriasis Drugs Market, by Patient Type

  • 10.1. Adults
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Psoriasis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies
  • 11.4. Specialty Pharmacies

12. Psoriasis Drugs Market, by Treatment Setting

  • 12.1. Home-Based Treatment
  • 12.2. Hospital-Based Care
  • 12.3. Specialty Dermatology Clinics

13. Psoriasis Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Psoriasis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Psoriasis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Almirall S.A.
  • 17.3. Amgen Inc
  • 17.4. AstraZeneca PLC
  • 17.5. Bausch Health Companies Inc.
  • 17.6. Biogen Inc.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Celltrion, Inc.
  • 17.10. Dermavant Sciences Ltd.
  • 17.11. Eli Lilly and Company
  • 17.12. Fresenius Kabi AG
  • 17.13. GlaxoSmithKline plc
  • 17.14. Glenmark Pharmaceuticals Ltd.
  • 17.15. Incyte Corporation
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. LEO Pharma A/S
  • 17.18. Lupin Limited
  • 17.19. Merck & Co., Inc.
  • 17.20. Mitsubishi Tanabe Pharma Corporation
  • 17.21. Novartis AG
  • 17.22. Pfizer Inc.
  • 17.23. Samsung Bioepis Co., Ltd.
  • 17.24. Sanofi S.A.
  • 17.25. Sun Pharmaceutical Industries Ltd
  • 17.26. Takeda Pharmaceutical Company Limited
  • 17.27. UCB S.A.
  • 17.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IL 17 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IL 17 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IL 17 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IL 23 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IL 23 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IL 23 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FOAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FOAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FOAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NAIL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NAIL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NAIL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SCALP PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SCALP PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SCALP PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOME-BASED TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOME-BASED TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOME-BASED TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITAL-BASED CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL-BASED CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITAL-BASED CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SPECIALTY DERMATOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SPECIALTY DERMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SPECIALTY DERMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 238. G7 PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 250. NATO PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. NATO PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. CANADA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 287. MEXICO PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. MEXICO PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 291. MEXICO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. MEXICO PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 293. MEXICO PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 305. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 323. GERMANY PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. GERMANY PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 325. GERMANY PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 326. GERMANY PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 327. GERMANY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 335. FRANCE PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. FRANCE PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 337. FRANCE PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 338. FRANCE PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 339. FRANCE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. FRANCE PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 341. FRANCE PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 342. FRANCE PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 343. FRANCE PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. FRANCE PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 347. RUSSIA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 349. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 350. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 351. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 352. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 353. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 354. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 355. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 359. ITALY PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 360. ITALY PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 361. ITALY PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 362. ITALY PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 363. ITALY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 364. ITALY PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 365. ITALY PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 366. ITALY PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 367. ITALY PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 368. ITALY PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 369. ITALY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 370. ITALY PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 371. SPAIN PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 372. SPAIN PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 373. SPAIN PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 374. SPAIN PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 375. SPAIN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 376. SPAIN PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 377. SPAIN PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 378. SPAIN PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 379. SPAIN PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 380. SPAIN PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 381. SPAIN PSORIASIS DRUGS